Enhancing clipping solutions for durable long-term patient outcomes

Sponsored by Abbott

Anchorperson: D. Tchetche

Spokesperson: V. Delgado

Summary

This EuroPCR 2025 session delves into the evolving strategies for mitral and tricuspid TEER, backed by fresh data and real-world insights. Review the latest evidence from the TRILUMINATE Pivotal and bRIGHT studies, and see how TR phenotypes can guide patient selection for more durable outcomes. Discover where RESHAPE-HF2 fits in today’s post-COAPT landscape and what it means for SMR management. The session also includes two illustrative MitraClip cases—one with a late referral—plus a focused look at clinical practice and long-term management, to help optimise your approach to structural heart care.

Learning Objectives

To review the clinical outcomes and patient benefits observed in recent mitral and tricuspid TEER studies
To debate how real-world experience fits in randomised clinical trials performed on secondary mitral regurgitation and STR patients
To discuss contemporary clinical practice for durable and successful TEER patient management

Speaker

D. Tchetche

Welcome and session objectives